The FDA approved Exelixis' cabonzantinib as a treatment for progressive, metastatic medullary thyroid cancer. The drug, which will be marketed as Cometriq, inhibits abnormal kinase proteins linked to the growth and development of cancer cells. Exelixis is also considering developing the drug for other types of cancer including multiple myeloma.